Syndax forecasts 2026 R&D and SG&A expenses of $400 million, excluding $50 million in stock option expense
SNDX•Syndax forecasts 2026 research and development, selling, general and administrative expenses of $400 million, excluding $50 million in expected stock-option expense. Third-quarter revenue rose to $83.3 million from $45.9 million a year earlier.
1. Expense outlook and revenue
Syndax Pharmaceuticals forecasts 2026 research and development, selling, general and administrative expenses of $400 million, excluding $50 million in expected stock-option expense. Third-quarter revenue rose to $83.3 million from $45.9 million a year earlier; Niktimvo collaboration revenue was $22.6 million in the quarter and is annualizing at more than $90 million. The company expects Revuforj peak annual U.S. net revenue to exceed $2 billion and reported cash and equivalents of $551.1 million as of September 30, 2026.
